Skip to main content
SpringerLink
Log in
SpringerLink
Log in

Current Clinical Progress — Podophyllotoxins

  • Chapter
Cancer Chemotherapy and Selective Drug Development

Part of the book series: Developments in Oncology ((DION,volume 23))

  • 17 Accesses

Abstract

Podophyllotoxin is a compound derived from the roots or rhyzomes of certain plants of the genus Podophyllum (Mandrake, American May apple). VP-16, or etoposide, and VM-26, or teniposide, are semisynthetic derivatives of podophyllotoxin. They differ from the parent compound podophyllotoxin and other classical spindle poisons such as colchicine, vincristine, and vinblastine by not interacting with tubulin or interfering with microtubule assembly (1).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Locke, J. D., Horwitz, S. B.: Effect of VP-16-213 on Microtubule Assembly in vitro and Nucleoside Transport in HeLa Cells. Biochemistry 15: 5435, 1976a.

    Article  Google Scholar 

  2. Comis, R. L.: Small Cell Carcinoma of the Lung. Cancer Treat. Rev. 9: 237–258, 1982.

    Article  PubMed  CAS  Google Scholar 

  3. Cohen, M. H., Broder, L. E., Fossieck, B. E., Ihde, D. C., Minna, J. D.: Phase II Clinical Trial of Weekly Administration of VP-16-213 in Small Cell Bronchogenic Carcinoma. Cancer Treat. Rep. 61: 489–490, 1977.

    PubMed  CAS  Google Scholar 

  4. Tucker, R. K., Ferguson, A., VanWyk, C., Sealy, R., Hewitsen, R., Levin, W.: Chemotherapy of Small Cell Carcinoma of the Lung with VP-16-213. Cancer 41: 1710–1714, 1978.

    Article  PubMed  CAS  Google Scholar 

  5. Tempero, M., Kessinger, A., Lemon, H. M.: VP-16-213 Therapy in Patients with Small Cell Carcinoma of the Lung After Failure on Combination Chemotherapy. Cancer Clin. Trials 4: 155–157, 1981.

    PubMed  CAS  Google Scholar 

  6. Evans, W. K., Osoba, D., Feld, R., Shephard, F. A.: VP-16 Alone and in Combination with Cisplatin (P) for Relapse in Small cell Lung Cancer (SCLC). Proc. The III World Conference on Lung Cancer, p. 218, 1982.

    Google Scholar 

  7. Tinsley, R., Comis, R., DiFino, S., Ginsberg, S., Gullo, J., Hickes, R., Poiesz, B., Rudolph, A., Issell, B., Lee, F.: Potential Clinical Synergy Observed in the Treatment of Small Cell Lung Cancer (SCLC) with Cisplatin (P) and VP-16–213 (V). Proc. ASCO 2: 198, 1983.

    Google Scholar 

  8. Lopez, J. A., Mann, J., Grapski, R., Krikorian, J. G.: Salvage Chemotherapy of Refractory Small Cell Lung Cancer (SCLC) with VP-16 and Cis-Platinum (DDP). Proc. ASCO 1: 151, 1982.

    Google Scholar 

  9. U.S. Dept. Health and Human Service. Compilation of Experimental Cancer Therapy Protocol Summaries, 7th edition, 1983.

    Google Scholar 

  10. Aisner, J., Whitacre, M., VanEcho, D. A., Wesley, M., Wiernik, P.H.: Doxorubicin, Cyclophosphamide and VP-16-213 (ACE) in the Treatment of Small cell Lung Cancer. Cancer Chemother. Pharmacol. 7: 187–193, 1982.

    PubMed  CAS  Google Scholar 

  11. Woods, R. L., Fox, R. M., Trattersall, M. H. N.: Treatment of Small Cell Bronchogenic Carcinoma with VM-26. Cancer Treat. Rep. 63: 2011, 1979.

    PubMed  CAS  Google Scholar 

  12. Fitzharris, B. M., Kaye, S. B., Saverymuttu, S., Newlands, E. S., Barrett, A., Peckham, M. J., McElwain, T.J.: VP-16-213 as a Single Agent in Advanced Testicular Tumors. Eur. J. Cancer 16: 1193, 1980.

    PubMed  CAS  Google Scholar 

  13. Williams, S. D., Einhorn, L. H., Greco, F. A., Oldham, R., Fletcher, R.: VP-16-213 Salvage Therapy for Refractory Germinal Neoplasms. Cancer 46: 2154–2158, 1980.

    Article  PubMed  CAS  Google Scholar 

  14. Bender, R. A., Anderson, T., Fisher, R. T., Young, R. C.: The Activity of the Epipodophyllotoxin VP-16 in the Treatment of Combination Chemotherapy Resistant Non-Hodgkin’s Lymphoma. Am. J. Hematol. 5: 203, 1978.

    Article  PubMed  CAS  Google Scholar 

  15. Cabanillas, F., Hagemeister, F. B., Bodey, G. P., Freireich, E. J.: IMVP- 16: An Effective Regimen for Patients with Lymphoma who have Relapsed after Initial Combination Chemotherapy. Blood 60: 693–697, 1982.

    PubMed  CAS  Google Scholar 

  16. Santoro, A., Bonfante, V., Bonadonna, G.: Third-Line Chemotherapy with CCNU, Etoposide and Prednimustine (CEP) in Hodgkin’s Disease (HD) Resistant to MOPP and ABVD. Proc. ASCO 1: 165, 1982.

    Google Scholar 

  17. Fisher, R. I., DeVita, V. T., Huybbard, S. M., Longo, D. L., Wesley, R., Chabner, B. A., Young, R. C.: Diffuse Aggressive Lymphomas: Increased Survival After Alternating Flexible Sequences of ProMACE and MOPP Chemotherapy. Annals of Int. Med. 98: 304–309, 1983.

    CAS  Google Scholar 

  18. Chiuten, D. F., Bennett, J. M., Creech, R. H., Glick, J., Falkson, G., Brodovsky, H. S., Begg, C. G., Muggia, F. M., Carbone, P. O.: VM-26, A New Anticancer Drug with Effectiveness in Malignant Lymphoma: An Eastern Cooperative Oncology Group Study (EST 1474). Cancer Treat. Rep 63: 7, 1979.

    PubMed  CAS  Google Scholar 

  19. The Australian and New Zealand Lymphoma Cooperative Chemotherapy Study Group: Comparison of the Use of Teniposide and Vincristine in Combination Chemotherapy for Non-Hodgkinfs Lymphoma. Cancer Treat. Rep. 66: 49–55, 1982.

    Google Scholar 

  20. Rivera, G., Dahl, G. V., Bowman, W. P., Avery, T. L., Wood, A., Aur, R. J.: VM-26 and Cytosine Arabinoside Combination Chemotherapy for Initial Induction Failures in Childhood Lymphocytic Leukemia. Cancer 46: 1727, 1980.

    CAS  Google Scholar 

  21. Bernasconi, C., Lazzarino, M., Morra, E.: The Use of an Epipodophyllotoxin Derivative (VP-16-213) in the Treatment of Acute Monocytic and Myelomonocytic Leukemias. In: Stacher, A., Hocker, P. (Hrsg) Erkrankungen der Myelopoese-Leukemien, Myeloproliferatives Syndrom, Polyzythamie. Urban and Schwarzenerg, Muchen, Berlin, S 224.

    Google Scholar 

  22. Hayes, F. A., Green, A. A., Casper, J., Cornet, J., Evans, W. E.: Clinical Evaluation of Sequentially Scheduled Cisplatin and VM-26 in Neuroblastoma: Response and Toxicity. Cancer 48: 1715–1718, 1981.

    Article  PubMed  CAS  Google Scholar 

  23. Spremulli, E., Schulz, J. J., Speckhart, V. J., Wampler, G. L.: Phase II Study of VM-26 in Adult Malignancies. Cancer Treat. Rep. 64: 147, 1980.

    PubMed  CAS  Google Scholar 

  24. Gerosa, M. S., DiStefano, E., Olivi, A.: VM-26 Monochemotherapy Trial in the Treatment of Recurrent Supratentorial Gliomas: Preliminary Report. Surg. Neurol. 15: 128, 1981.

    Article  CAS  Google Scholar 

  25. Sweet, D. L., Hendler, F. J., Hanlon, K., Hekmatpanah, J., Griem, M. L., Duda, E. E., Mulligan, B., Wollman, R. L.: Treatment of Grade III and IV Astrocytomas with BCNU Alone and in Combination with VM-26 Following Surgery and Radiation Therapy. Cancer Treat. Rep. 63: 1707–1711, 1979.

    PubMed  CAS  Google Scholar 

  26. Schell, F. C., Yap, H. Y., Hortobagyi, G. N., Issell, B., Esparza, L.: Phase II Study of VP-16-213 (Etoposide) in Refractory Metastatic Breast Carcinoma. Cancer Chemother. Pharmacol. 7: 223–225, 1982.

    Article  PubMed  CAS  Google Scholar 

  27. Vaughn, C. B., Greb, E. M., Lockhard, C., Groshko, G., Enochs, K., Duffin, H., Demitrish, M.: VP-16 and Adriamycin in Patients with Advanced Breast Cancer. Am. J. Clin. Oncol. (CCT) 5: 505–507, 1982.

    CAS  Google Scholar 

  28. Konits, P. H., VanEcho, D. A., Aisner, J., Morris, D., Wiernik, P. H.: Doxorubicin Plus VP-16-213 for the Treatment of Refractory Breast Carcinoma. Am. J. Clin. Oncol. (CCT) 5: 515–519, 1982.

    CAS  Google Scholar 

  29. Laubenstein, L. J., Krigel, R. L., Hymes, K. B., Muggia, F. M.: Treatment of Epidemic Kaposi’s Sarcoma with VP-16-213 (Etoposide) and a Combination of Doxorubicin, Bleomycin, and Vinblastine (ABV). Proc. ASCO 2: 228, 1983.

    Google Scholar 

  30. Commers, J. R., Foley, J. F.: Pulmonary Hyaline Membrane Disease Occurring in the Course of VM-26 Therapy. Cancer Treat. Rep. 63: 1093, 1979.

    Google Scholar 

Download references

Authors
  1. Brian F. Issell
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

K. R. Harrap W. Davis A. H. Calvert

Rights and permissions

Reprints and permissions

Copyright information

© 1984 Martinus Nijhoff Publishing, Boston

About this chapter

Cite this chapter

Issell, B.F. (1984). Current Clinical Progress — Podophyllotoxins. In: Harrap, K.R., Davis, W., Calvert, A.H. (eds) Cancer Chemotherapy and Selective Drug Development. Developments in Oncology, vol 23. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-3837-6_8

Download citation

  • DOI: https://doi.org/10.1007/978-1-4613-3837-6_8

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-3839-0

  • Online ISBN: 978-1-4613-3837-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation